Identification

Name
Fenoterol
Accession Number
DB01288
Type
Small Molecule
Groups
Approved, Investigational
Description

An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem]

Structure
Thumb
Synonyms
  • 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane
  • 1-(P-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane
  • 3,5-Dihydroxy-alpha-(((P-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol
  • 5-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol
  • Fenoterolum
  • Phenoterol
Product Ingredients
IngredientUNIICASInChI Key
Fenoterol hydrobromideRLI45Z99RB1944-12-3SGZRQMALQBXAIQ-NRNQBQMASA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Berotec 1mg/mlSolution1 mgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1982-12-312008-12-16Canada
Berotec Aem 100mcg/doseAerosol, metered100 mcgOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1992-12-312007-11-02Canada
Berotec Forte Metered AerAerosol, metered0.2 mgOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1977-12-311997-08-14Canada
Berotec Tab 2.5mgTablet2.5 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1979-12-312000-07-31Canada
Berotec Udv Inhalation Solution 0.25mg/mlSolution0.25 mgOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1994-12-312005-02-10Canada
Berotec Udv Inhalation Soluton 0.625mg/mlSolution0.625 mgOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1994-12-312004-07-16Canada
International/Other Brands
Alveofen (Prieto) / Berotec (Boehringer Ingelheim) / Berotec N (Boehringer Ingelheim) / Cenfenol (Center) / Partusisten (Boehringer Ingelheim)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Duovent UdvFenoterol hydrobromide (0.3125 mg) + Ipratropium bromide (0.125 mg)SolutionOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1995-12-312017-01-31Canada
Categories
UNII
22M9P70OQ9
CAS number
13392-18-2
Weight
Average: 303.3529
Monoisotopic: 303.147058165
Chemical Formula
C17H21NO4
InChI Key
LSLYOANBFKQKPT-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
IUPAC Name
5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol
SMILES
CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1

Pharmacology

Indication

Fenoterol is used for the treatment of asthma.

Structured Indications
Pharmacodynamics

Fenoterol is a beta agonist designed to open up the airways to the lungs by decreasing bronchconstriction.

Mechanism of action

Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
UBeta-1 adrenergic receptor
agonist
Human
UBeta-3 adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Fenoterol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Fenoterol.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Fenoterol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Fenoterol.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fenoterol.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fenoterol.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Fenoterol.Approved, Illicit
AtenololAtenolol may decrease the bronchodilatory activities of Fenoterol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Fenoterol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Fenoterol is combined with Atosiban.Approved, Investigational
BendroflumethiazideFenoterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Fenoterol.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Fenoterol.Approved, Illicit
Benzylpenicilloyl PolylysineFenoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Fenoterol can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Fenoterol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Fenoterol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Fenoterol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Fenoterol.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Fenoterol.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Fenoterol is combined with Bucindolol.Investigational
BumetanideFenoterol may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Fenoterol.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Fenoterol.Approved
CabergolineCabergoline may increase the hypertensive activities of Fenoterol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Fenoterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Fenoterol.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
ChlorothiazideFenoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorthalidoneFenoterol may increase the hypokalemic activities of Chlorthalidone.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fenoterol.Approved, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Fenoterol.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenoterol.Approved
CyclopenthiazideFenoterol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenoterol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Fenoterol.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Fenoterol.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Fenoterol.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Fenoterol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Fenoterol.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Fenoterol.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Fenoterol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fenoterol.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Fenoterol.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Fenoterol.Approved
EpanololThe risk or severity of adverse effects can be increased when Fenoterol is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Fenoterol.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Fenoterol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Fenoterol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Fenoterol.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Fenoterol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Fenoterol.Approved
Etacrynic acidFenoterol may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Etilefrine.Withdrawn
FenozoloneThe risk or severity of adverse effects can be increased when Fenoterol is combined with Fenozolone.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol.Approved, Investigational, Vet Approved
FurosemideFenoterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Fenoterol.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Fenoterol.Experimental
HydrochlorothiazideFenoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFenoterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Hydroxyamphetamine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenoterol.Approved
IndapamideFenoterol may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Fenoterol.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fenoterol.Approved, Investigational
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Fenoterol.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Fenoterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenoterol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fenoterol.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Fenoterol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenoterol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Fenoterol.Approved
LinezolidLinezolid may increase the hypertensive activities of Fenoterol.Approved, Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Fenoterol.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Loxapine.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Fenoterol.Withdrawn
MefenorexThe risk or severity of adverse effects can be increased when Fenoterol is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Mephentermine.Approved
MepindololMepindolol may decrease the bronchodilatory activities of Fenoterol.Experimental
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Fenoterol.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Fenoterol.Approved, Investigational
MethyclothiazideFenoterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Fenoterol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Fenoterol.Approved
MetolazoneFenoterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Fenoterol.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Fenoterol.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Fenoterol.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fenoterol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fenoterol.Approved
NabiloneNabilone may increase the tachycardic activities of Fenoterol.Approved, Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Fenoterol.Withdrawn
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Fenoterol.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fenoterol.Approved
NylidrinThe risk or severity of adverse effects can be increased when Fenoterol is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Fenoterol.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Fenoterol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Fenoterol.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Fenoterol.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenoterol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenoterol.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenoterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Fenoterol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Fenoterol.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Fenoterol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Fenoterol.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Fenoterol.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Fenoterol.Approved, Vet Approved, Withdrawn
PiretanideFenoterol may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Fenoterol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Fenoterol.Withdrawn
PolythiazideFenoterol may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Fenoterol.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Prenalterol.Experimental
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fenoterol.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Procaterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Pseudoephedrine.Approved
QuinethazoneFenoterol may increase the hypokalemic activities of Quinethazone.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenoterol.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Fenoterol.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Fenoterol.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fenoterol.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Fenoterol.Approved
SotalolSotalol may decrease the bronchodilatory activities of Fenoterol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Fenoterol.Approved
SynephrineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Fenoterol.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Fenoterol.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Fenoterol.Experimental
TetryzolineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Fenoterol.Approved, Investigational
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Fenoterol.Approved
TorasemideFenoterol may increase the hypokalemic activities of Torasemide.Approved
TramazolineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tramazoline.Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fenoterol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tretoquinol.Experimental
TrichlormethiazideFenoterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Fenoterol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenoterol.Approved
TyramineThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Fenoterol.Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fenoterol.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Fenoterol.Approved
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Zeile, K., Thoma, O. and Mentrup, A,; U.S. Patent 3,341,593; September 12, 1967; assigned to Boehringer lngelheim GmbH, Germany.

General References
Not Available
External Links
Human Metabolome Database
HMDB15405
PubChem Compound
3343
PubChem Substance
46509099
ChemSpider
3226
BindingDB
50131281
ChEBI
149226
ChEMBL
CHEMBL32800
Therapeutic Targets Database
DAP000946
PharmGKB
PA10079
IUPHAR
557
Guide to Pharmacology
GtP Drug Page
Wikipedia
Fenoterol
ATC Codes
R03AL01 — Fenoterol and ipratropium bromideR03CC04 — FenoterolR03AC04 — FenoterolG02CA03 — Fenoterol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAsthma Bronchial1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionRespiratory (inhalation)1 mg
Aerosol, meteredOral; Respiratory (inhalation)100 mcg
Aerosol, meteredOral; Respiratory (inhalation)0.2 mg
TabletOral2.5 mg
SolutionOral; Respiratory (inhalation)0.25 mg
SolutionOral; Respiratory (inhalation)0.625 mg
SolutionOral; Respiratory (inhalation)
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)222-223Zeile, K., Thoma, O. and Mentrup, A,; U.S. Patent 3,341,593; September 12, 1967; assigned to Boehringer lngelheim GmbH, Germany.
Predicted Properties
PropertyValueSource
Water Solubility0.162 mg/mLALOGPS
logP1.36ALOGPS
logP1.47ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)8.85ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area92.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85 m3·mol-1ChemAxon
Polarizability31.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier-0.9294
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7292
P-glycoprotein inhibitor INon-inhibitor0.9064
P-glycoprotein inhibitor IINon-inhibitor0.946
Renal organic cation transporterNon-inhibitor0.7992
CYP450 2C9 substrateNon-substrate0.7004
CYP450 2D6 substrateNon-substrate0.7055
CYP450 3A4 substrateNon-substrate0.625
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.8609
CarcinogenicityNon-carcinogens0.9011
BiodegradationNot ready biodegradable0.9174
Rat acute toxicity2.1550 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.813
hERG inhibition (predictor II)Non-inhibitor0.7963
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-7c86ed90b231db502424
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-cbe10ada4ea45a1c990b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900000000-d901c2f8d4959edd3fb8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900000000-5c754c51c284fa4a611f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-3900000000-8521f3088ff1f180cc5b

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Resorcinols / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
show 1 more
Substituents
Amphetamine or derivatives / Phenylpropane / Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amino compound, resorcinols (CHEBI:149226)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. de Vries B, Roffel AF, Zaagsma J, Meurs H: Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle. Eur J Pharmacol. 2001 Nov 23;431(3):353-9. [PubMed:11730729]
  2. Boterman M, Smits SR, Meurs H, Zaagsma J: Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle. Eur J Pharmacol. 2006 Jan 4;529(1-3):151-6. Epub 2005 Dec 1. [PubMed:16324695]
  3. Marone G, Ambrosio G, Bonaduce D, Genovese A, Triggiani M, Condorelli M: Inhibition of IgE-mediated histamine release from human basophils and mast cells by fenoterol. Int Arch Allergy Appl Immunol. 1984;74(4):356-61. [PubMed:6203844]
  4. Coqueret O, Demarquay D, Lagente V: Role of cyclic AMP in the modulation of IgE production by the beta 2-adrenoceptor agonist, fenoterol. Eur Respir J. 1996 Feb;9(2):220-5. [PubMed:8777955]
  5. Bouillon T, Meineke I, Port R, Hildebrandt R, Gunther K, Gundert-Remy U: Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Eur J Clin Pharmacol. 1996;51(2):153-60. [PubMed:8911881]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Drug created on June 28, 2007 09:56 / Updated on December 01, 2017 17:20